Additionally, FAK has been implicated in mediating primary resistance to sorafenib; its activation enhances the Wnt/β-catenin signaling pathway, thereby promoting tumor stemness, recurrence, and therapeutic resistance (38). The gene discussed is PTK2; the disease is neoplasm.